<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700852</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A01877-32</org_study_id>
    <nct_id>NCT04700852</nct_id>
  </id_info>
  <brief_title>Efficacy of Puressentiel Protective Nasal Spray in Allergic Rhinitis</brief_title>
  <acronym>EPPNS</acronym>
  <official_title>Efficacy of Puressentiel Protective Nasal Spray on Symptoms and Inflammation in Patients With in Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puressentiel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Puressentiel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a proof o concept aiming to determine the efficacy of Puressentiel nasal&#xD;
      protective spray (PNPS) in patients with allergic rhinitis.&#xD;
&#xD;
      Cross over study, with a nasal provocative test (NPT) in patients with allergic rhinitis&#xD;
      sensitized to grass pollen. A day 0 (first NPT) the following outcomes are recorded: allergic&#xD;
      Rhinitis control test (ARCT) and Inspiratory nasal peak flow (INPF) before and 30 min after&#xD;
      the NPT. Nasal lavage is performed 30 min after the NPT and 3 cytokines (IL4, IL5 and IL13&#xD;
      are measured by ELISA.&#xD;
&#xD;
      An other NPT is performed at day 30 and the same outcomes measured.&#xD;
&#xD;
      30 min before NPT 2 nasal sprays of PNPS are administered in each nostril in a randomized&#xD;
      manner and cross over, the patient being is own control.&#xD;
&#xD;
      The primary outcomes ins the IL4, IL5 and IL13 concentrations in the nasal lavage. ARCT and&#xD;
      INPF are the secondary outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in concentration of IL-13 in the nasal lavage will be assessed</measure>
    <time_frame>measurements at day 1 and day 30</time_frame>
    <description>measurement by ELISA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of IL-5 in the nasal lavage will be assessed</measure>
    <time_frame>Day1 and Day30</time_frame>
    <description>Measurement by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of IL-4 in the nasal lavage will be assessed</measure>
    <time_frame>Day1 and Day 30</time_frame>
    <description>Measurement by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nasal Inspiratory Peak Flow will be assessed</measure>
    <time_frame>Day 1 and Day 30</time_frame>
    <description>Measurement with a peak flow meter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Allergic Rhinitis Control test (ARCT) will be assessed</measure>
    <time_frame>Day 1 and day 2</time_frame>
    <description>5 questions questionnaire score from 0 to 25 (0 worse score), 25 (best score)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Allergic Rhinitis Due to Grass Pollen</condition>
  <condition>Allergic Inflammation</condition>
  <arm_group>
    <arm_group_label>allergic rhinitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Puressentiel protective nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Puressentiel protective nasal spray</intervention_name>
    <description>provocative nasal test with grass pollen and nasal lavage</description>
    <arm_group_label>allergic rhinitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with diagnostic of allergic rhinitis sensitized to grass pollen for more than&#xD;
             one year with or without associated asthma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients sensitized to a perrianual allergen&#xD;
&#xD;
          -  patients with viral infection 4 weeks before inclusion&#xD;
&#xD;
          -  patients with severe non controlled asthma&#xD;
&#xD;
          -  patients with chronic sinusitis&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
&#xD;
          -  patients with hypersensitivity to essential oil (eucalyptus radie)&#xD;
&#xD;
          -  epileptic patient&#xD;
&#xD;
          -  patients treated with nasal corticosteroid or anti-histamine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Davide Caimmi, MD</last_name>
    <phone>33630061134</phone>
    <email>davide.caimmi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth Simon, PhD</last_name>
    <phone>33144405528</phone>
    <email>e.simon@puressentiel.com</email>
  </overall_contact_backup>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

